Canada's public drug plans shouldn't cover new Alzheimer's drug, agency says
Public drug plans should not cover lecanemab, a drug to slow early-stage Alzheimer’s disease, Canada’s Drug Agency says in its draft recommendation.
Related Posts
Jonathan Haidt says Zuckerberg trial could finally hold Big Tech accountable for the harm done to young users
Montreal hospital recognized for efforts to improve emergency care for seniors
